Together, through ChaC1-based drug screening strategy, we identified a synergistic lethal effect of auranofin and proteasome inhibitors in HCC cells, suggesting that combination of these drugs might be repurposed for HCC treatment. Here, CHAC1 is linked to hepatocellular carcinoma.